Navigation Links
Metformin Outperforms Common Class of Diabetes Drugs in Study
Date:6/24/2012

SUNDAY, June 24 (HealthDay News) -- Three widely used diabetes drugs are associated with a greater risk of death when compared to a popular drug from a different class, metformin, according to a new study.

Researchers analyzed data from nearly 24,000 patients with type 2 diabetes, average age 62, who were treated with one of three drugs called sulfonylureas (glipizide, glyburide, and glimepiride) or with another type of drug called metformin.

Sulfonylureas help decrease blood sugar levels by stimulating the pancreas to produce insulin. Metformin also helps reduce blood sugar levels.

Overall, all three sulfonylureas were associated with a more than 50 percent greater risk of death compared to metformin, according to the study, which was funded by drug company Astra Zeneca.

The researchers also found that, among diabetes patients with heart disease, glipizide was associated with a 41 percent greater risk of death and glyburide was associated with a 38 percent greater risk of death, compared with glimepiride and metformin.

According to one expert not connected to the study, the new data could provide some guidance for patients.

"Patients taking sulfonylureas should be made aware of this increased risk of death and other oral options for glycemic [blood sugar] control should be discussed," said Dr. Spyros Mezitis, an endocrinologist at Lenox Hill Hospital in New York City.

The study was to be presented Sunday at The Endocrine Society's annual meeting in Houston.

"We have clearly demonstrated that metformin is associated with a substantial reduction in mortality risk, and, thus, should be the preferred first-line agent, if one has a choice between metformin and a sulfonylurea," said study author Dr. Kevin M. Pantalone, an endocrinologist at Summa Western Reserve Hospital in Cuyahoga Falls, Ohio.

He conducted the study with a team of researchers from Cleveland Clinic.

Another expert said the study may have "enormous clinical implications."

Dr. Minisha Sood, also an endocrinologist at Lenox Hill, said that sulfonylureas may fare worse than metformin because the former might "interfere" with cardiovascular processes that strengthen and protect heart tissue so it becomes more resilient should a cardiac event occur.

"What's interesting about this study is that all three sulfonylureas examined led to increased mortality rates vs. metformin in the entire cohort study, which included patients without coronary artery disease," Sood added. "Does this mean that we shouldn't be prescribing sulfonylureas at all? I think prospective trials are needed to answer that question, so the jury is still out."

Nearly 26 million people in the United States have diabetes, according to the U.S. Centers for Disease Control and Prevention. Many of these patients also have other health problems, including heart disease.

Findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about diabetes medicines.

-- Robert Preidt

SOURCES: Spyros Mezitis, M.D., and Minisha Sood, M.D., endocrinologists, Lenox Hill Hospital, New York City; The Endocrine Society, news release, June 24, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
2. Texting in College Classrooms Common, Distracting
3. Recovery from propofol anesthesia may be sped by use of common stimulant
4. Long-term neuropsychological impairment is common in acute lung injury survivors
5. Overuse Injuries Common Among Female College Athletes
6. Common Blood Pressure Drug Safe for Heart Failure: Study
7. Test links strains of common parasite to severe illness in US newborns
8. Common Plastics Chemical Might Boost Diabetes Risk
9. Off-Label Drug Use Appears Common
10. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
11. Slow-growing babies more likely in normal-weight women; Less common in obese pregnancies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Metformin Outperforms Common Class of Diabetes Drugs in Study
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based payments, ... are unsure how to move forward, given the need to sustain current operations. ... tailored to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
(Date:6/23/2016)... June 23, 2016  Guerbet announced today that it ... Supplier Horizon Award . One of 12 ... recognized for its support of Premier members through exceptional ... excellence, and commitment to lower costs. ... recognition of our outstanding customer service from Premier," says ...
(Date:6/23/2016)... FRANKLIN, Tenn. , June 23, 2016 ... for automating, integrating and transforming the patient ... launch of several innovative new products and ... depth of its revenue cycle offerings. These ... establish more efficient workflows, remain compliant in ...
Breaking Medicine Technology: